moderately severe hemophilia A

Summary

moderately severe hemophilia A (MONDO:0015720) is a disease with 1 cohort gene.

At a glance

• Cohort genes: 1
• Phenotypes (HPO): 26

Clinical features

Signs & symptoms

Clinical features (HPO)

26 HPO clinical features (Orphanet curated; top 26 by frequency):

HPO ID	Term	Frequency
HP:0001892	Abnormal bleeding	Very frequent (80-99%)
HP:0003125	Reduced factor VIII activity	Very frequent (80-99%)
HP:0003645	Prolonged partial thromboplastin time	Very frequent (80-99%)
HP:0000225	Gingival bleeding	Frequent (30-79%)
HP:0001933	Subcutaneous hemorrhage	Frequent (30-79%)
HP:0002829	Arthralgia	Frequent (30-79%)
HP:0005261	Joint hemorrhage	Frequent (30-79%)
HP:0011889	Bleeding with minor or no trauma	Frequent (30-79%)
HP:0012233	Intramuscular hematoma	Frequent (30-79%)
HP:0000790	Hematuria	Occasional (5-29%)
HP:0001376	Limitation of joint mobility	Occasional (5-29%)
HP:0001386	Joint swelling	Occasional (5-29%)
HP:0002170	Intracranial hemorrhage	Occasional (5-29%)
HP:0002239	Gastrointestinal hemorrhage	Occasional (5-29%)
HP:0002315	Headache	Occasional (5-29%)
HP:0003040	Arthropathy	Occasional (5-29%)
HP:0004846	Prolonged bleeding after surgery	Occasional (5-29%)
HP:0006298	Prolonged bleeding after dental extraction	Occasional (5-29%)
HP:0100309	Subdural hemorrhage	Occasional (5-29%)
HP:0100769	Synovitis	Occasional (5-29%)
HP:0100773	Cartilage destruction	Occasional (5-29%)
HP:0030746	Intraventricular hemorrhage	Very rare (<1-4%)
HP:0100310	Epidural hemorrhage	Very rare (<1-4%)
HP:0001250	Seizure	Very rare (<1-4%)
HP:0003273	Hip contracture	Very rare (<1-4%)
HP:0007420	Spontaneous hematomas	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	moderately severe hemophilia A
Mondo ID	MONDO:0015720
Orphanet	169805
UMLS	C0272323
MedGen	543974
GARD	0017060
Is cancer (heuristic)	no

Also known as: moderately severe factor VIII deficiency · moderately severe haemophilia type A · moderately severe hemophilia type A

Data availability: 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › X-linked disease › hemophilia A › moderately severe hemophilia A

Related subtypes (4): hemophilia A with vascular abnormality, severe hemophilia A, mild hemophilia A, symptomatic form of hemophilia A in female carriers

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 6 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
F8	Strong	X-linked	hemophilia A	6

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
F8	Orphanet:169802	Severe hemophilia A
F8	Orphanet:169805	Moderate hemophilia A
F8	Orphanet:169808	Mild hemophilia A
F8	Orphanet:177926	Bleeding disorder in hemophilia A carriers

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
F8	HGNC:3546	ENSG00000185010	P00451	Coagulation factor VIII	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
F8	Coagulation factor VIII	Factor VIII, along with calcium and phospholipid, acts as a cofactor for F9/factor IXa when it converts F10/factor X to the activated form, factor Xa.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
F8	Other/Unknown	no		FA58C, Cupredoxin, Galactose-bd-like_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
heart right ventricle	1
left ventricle myocardium	1
myocardium	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
F8	266	broad	marker	left ventricle myocardium, heart right ventricle, myocardium

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
F8	1,900

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
F8	P00451	25

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 16. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective F8 accelerates dissociation of the A2 domain	1	11420.0×	5e-04	F8
Defective F8 binding to the cell membrane	1	11420.0×	5e-04	F8
Defective F8 secretion	1	11420.0×	5e-04	F8
Defective F8 binding to von Willebrand factor	1	5710.0×	5e-04	F8
Defective factor IX causes thrombophilia	1	3806.7×	5e-04	F8
Defective F8 cleavage by thrombin	1	3806.7×	5e-04	F8
Defective cofactor function of FVIIIa variant	1	3806.7×	5e-04	F8
Defective F9 variant does not activate FX	1	3806.7×	5e-04	F8
Defective F8 sulfation at Y1699	1	3806.7×	5e-04	F8
Amplification and propagation of coagulation cascade	1	634.4×	0.003	F8
Initiation of coagulation cascade	1	475.8×	0.003	F8
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1	423.0×	0.003	F8
Cargo concentration in the ER	1	335.9×	0.004	F8
Regulation of clotting cascade	1	233.1×	0.005	F8
COPII-mediated vesicle transport	1	163.1×	0.007	F8
Platelet degranulation	1	87.8×	0.011	F8

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
blood coagulation, intrinsic pathway	1	2106.5×	0.001	F8
acute-phase response	1	421.3×	0.004	F8
blood coagulation	1	173.7×	0.006	F8

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
F8	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
F8	8	Binding:8

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	F8

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
F8	8	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.